HIV Trispecific Antibody
A reservoir-directed trispecific antibody strategy built around HIV target recognition, CD3 engagement, and CD28 co-stimulatory logic.
Application: HIV reservoir-directed therapeutic program.
Distinct therapeutic approaches with enabling formulation support.
Macro HRD organizes its technology around program-specific biology: HIV Trispecific Antibody, AH-D Enveloped Viruses, HPV Topical, and Advanced LNP Blood–Brain Barrier Crossing Lipid Nanoparticle Delivery Platform.
Different mechanisms, different development paths.
AH-D Peptide for Enveloped Viruses
A membrane-active peptide approach based on curvature-dependent pore formation in tightly curved nanoscale lipid membranes.
Application: Enveloped-virus indications where lipid-envelope targeting is mechanistically relevant.
Exploratory HPV Topical Program
A topical mucosal strategy for a non-enveloped virus, focused on local delivery, mucosal retention, epithelial penetration, and HPV-specific validation.
Application: Exploratory spray / gel approach for genital mucosal environments.
Proprietary Lipid Nanoparticle Drug Delivery Platform
Advanced LNP is formulation technology, not AH-D's mechanism and not the pipeline's primary antiviral mechanism.
Application: Enabling formulation support when payload, route, or tissue-access constraints make delivery important.
AI Support
GEDM3DQ supports structured development decisions.
GEDM3DQ supports modeling, simulation, evidence organization, and decision logic while biological validation, clinical review, and regulatory decision-making remain separate.